- Home
- SNDX vs WOOF Comparison
SNDX vs WOOF Comparison
Compare SNDX & WOOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- WOOF
- Stock Information
- Founded
- SNDX 2005
- WOOF 1965
- Country
- SNDX United States
- WOOF United States
- Employees
- SNDX N/A
- WOOF N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- WOOF Other Specialty Stores
- Sector
- SNDX Health Care
- WOOF Consumer Discretionary
- Exchange
- SNDX Nasdaq
- WOOF Nasdaq
- Market Cap
- SNDX 1.1B
- WOOF N/A
- IPO Year
- SNDX 2016
- WOOF 2021
- Fundamental
- Price
- SNDX $9.60
- WOOF $2.97
- Analyst Decision
- SNDX Strong Buy
- WOOF Buy
- Analyst Count
- SNDX 11
- WOOF 8
- Target Price
- SNDX $34.18
- WOOF $3.75
- AVG Volume (30 Days)
- SNDX 2.0M
- WOOF 3.9M
- Earning Date
- SNDX 07-31-2025
- WOOF 06-05-2025
- Dividend Yield
- SNDX N/A
- WOOF N/A
- EPS Growth
- SNDX N/A
- WOOF N/A
- EPS
- SNDX N/A
- WOOF N/A
- Revenue
- SNDX $43,722,000.00
- WOOF $6,080,721,000.00
- Revenue This Year
- SNDX $426.77
- WOOF $0.04
- Revenue Next Year
- SNDX $98.31
- WOOF $1.41
- P/E Ratio
- SNDX N/A
- WOOF N/A
- Revenue Growth
- SNDX N/A
- WOOF N/A
- 52 Week Low
- SNDX $8.58
- WOOF $2.23
- 52 Week High
- SNDX $25.07
- WOOF $6.29
- Technical
- Relative Strength Index (RSI)
- SNDX 48.99
- WOOF 50.41
- Support Level
- SNDX $8.59
- WOOF $2.97
- Resistance Level
- SNDX $10.01
- WOOF $3.16
- Average True Range (ATR)
- SNDX 0.54
- WOOF 0.12
- MACD
- SNDX 0.10
- WOOF 0.05
- Stochastic Oscillator
- SNDX 71.48
- WOOF 68.85
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.